Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries
Novo Nordisk A/S Common Stock
(NY:
NVO
)
38.16
-0.43 (-1.11%)
Official Closing Price
Updated: 7:00 PM EST, Feb 25, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
55,460,057
Open
37.71
Bid (Size)
38.08 (100)
Ask (Size)
38.09 (900)
Prev. Close
38.59
Today's Range
37.65 - 38.24
52wk Range
37.65 - 93.80
Shares Outstanding
N/A
Dividend Yield
3.06%
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Stock Market Today, Feb. 25: Novo Nordisk Dips After Announcing $2.1 Billion Partnership With Vivtex for Oral Drug-Delivery Technologies
↗
Today 18:12 EST
Investors weigh steep GLP‑1 price cuts against a multibillion‑dollar oral obesity push, fresh analyst caution, and a new partnership, today, Feb. 25, 2026.
Via
The Motley Fool
Topics
Stocks
Eli Lilly Just Took 2 Major Steps Forward in the Billion-Dollar Obesity Drug Market. Here's What You Need to Know.
↗
Today 14:35 EST
Eli Lilly has seen revenue and earnings soar in recent years.
Via
The Motley Fool
Performance
YTD
-27.2%
-27.2%
1 Month
-40.4%
-40.4%
3 Month
-21.7%
-21.7%
6 Month
-32.4%
-32.4%
1 Year
-58.0%
-58.0%
More News
Read More
1 Reason Why I'd Hold This Weight‑Loss Drug Leader Through Any Market Crash
↗
Today 13:20 EST
Via
The Motley Fool
Topics
Economy
NVO Investors Have Opportunity to Join Novo Nordisk A/S Fraud Investigation with the Schall Law Firm
Today 9:56 EST
From
Schall Law
Via
GlobeNewswire
Novo, Vivtex Ink $2.1 Billion Deal To Develop Oral Medicines For Obesity And Diabetes
↗
Today 8:29 EST
Via
Stocktwits
Novo Nordisk To Slash GLP-1 Drug Prices By Up To 50% In US Starting 2027
↗
Today 4:14 EST
Via
Benzinga
Could Novo Nordisk Help Turn $100,000 Into $1 Million in the GLP‑1 Gold Rush?
↗
Today 0:50 EST
Via
The Motley Fool
Why Eli Lilly Stock Slumped Today
↗
February 24, 2026
Via
The Motley Fool
Novo's 'Flashy' Ozempic, Wegovy Price Cuts Unlikely To Impact LLY Stock, Says BofA
↗
February 24, 2026
Via
Stocktwits
Novo Nordisk To Cut Ozempic, Wegovy Prices By Up To 50%: Report
↗
February 24, 2026
Via
Stocktwits
Topics
Artificial Intelligence
NVO Stock Continues To Decline Pre-Market After Monday’s Crash Amid CagriSema Setback – But Tuesday Brings Some Hope From China
↗
February 24, 2026
Via
Stocktwits
Got $5,000? Viking Therapeutics Might Be a Weight‑Loss Drug Moon Shot in the Making.
↗
February 23, 2026
Via
The Motley Fool
Stock Market Today, Feb. 23: Novo Nordisk Plunges 16% After Obesity Drug Falls Short
↗
February 23, 2026
Via
The Motley Fool
Topics
Stocks
Stock Market Today, Feb. 23: Nvidia Earnings Loom as Tariff Concerns Drive Dow 800 Points Lower
↗
February 23, 2026
Via
The Motley Fool
Topics
Artificial Intelligence
Government
Stocks
Novo Nordisk Shares Tumble 15.1% After CagriSema Fails to Topple Eli Lilly in Head-to-Head Trial
February 23, 2026
Via
MarketMinute
Check out the stocks that are attracting the most attention and driving market activity.
↗
February 23, 2026
Via
Chartmill
Why Viking Therapeutics Stock Is Up More Than 9% Today
↗
February 23, 2026
Via
The Motley Fool
Novo Nordisk A/S Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights – NVO
February 23, 2026
From
The DJS Law Group
Via
Business Wire
Why Eli Lilly Stock Just Popped
↗
February 23, 2026
Via
The Motley Fool
Why Novo Nordisk Stock Just Crashed
↗
February 23, 2026
Via
The Motley Fool
High Volatility and Earnings Crossroads: A Deep Dive into Hims & Hers Health (HIMS) in 2026
February 23, 2026
Via
Finterra
Topics
Artificial Intelligence
Intellectual Property
Lawsuit
NVO Investors Have Opportunity to Join Novo Nordisk A/S Fraud Investigation with the Schall Law Firm
February 23, 2026
From
The Schall Law Firm
Via
Business Wire
Eli Lilly Surges as Novo Nordisk’s "CagriSema" Stumbles in High-Stakes Obesity Head-to-Head
February 23, 2026
Via
MarketMinute
Novo Nordisk Shares Plunge 13% as Next-Gen Weight Loss Drug CagriSema Fails to Topple Eli Lilly in Landmark Trial
February 23, 2026
Via
MarketMinute
Topics
Earnings
These stocks are moving in today's pre-market session
↗
February 23, 2026
Via
Chartmill
Frequently Asked Questions
Is Novo Nordisk A/S Common Stock publicly traded?
Yes, Novo Nordisk A/S Common Stock is publicly traded.
What exchange does Novo Nordisk A/S Common Stock trade on?
Novo Nordisk A/S Common Stock trades on the New York Stock Exchange
What is the ticker symbol for Novo Nordisk A/S Common Stock?
The ticker symbol for Novo Nordisk A/S Common Stock is NVO on the New York Stock Exchange
What is the current price of Novo Nordisk A/S Common Stock?
The current price of Novo Nordisk A/S Common Stock is 38.16
When was Novo Nordisk A/S Common Stock last traded?
The last trade of Novo Nordisk A/S Common Stock was at 02/25/26 07:00 PM ET
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.